Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) Overview | 11 | 1 |
| Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) Comparative Analysis | 12 | 1 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics under Development by Companies | 13 | 2 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Pipeline Products Glance | 16 | 4 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Unknown Stage Products | 19 | 1 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Products under Development by Companies | 20 | 2 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Products under Investigation by Universities/Institutes | 22 | 1 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Companies Involved in Therapeutics Development | 23 | 25 |
| Arisaph Pharmaceuticals, Inc. | 23 | 1 |
| AstraZeneca Plc | 24 | 1 |
| Betagenon AB | 25 | 1 |
| Can-Fite BioPharma Ltd. | 26 | 1 |
| Cerenis Therapeutics Holding SA | 27 | 1 |
| Conatus Pharmaceuticals Inc. | 28 | 1 |
| Corcept Therapeutics Incorporated | 29 | 1 |
| Daewoong Pharmaceutical Co., Ltd. | 30 | 1 |
| Dimerix Bioscience Pty Ltd | 31 | 1 |
| Dr. Falk Pharma GmbH | 32 | 1 |
| DURECT Corporation | 33 | 1 |
| Eternygen GmbH | 34 | 1 |
| Galmed Pharmaceuticals Ltd. | 35 | 1 |
| Huons Co., Ltd. | 36 | 1 |
| Kyorin Pharmaceutical Co., Ltd. | 37 | 1 |
| Matinas BioPharma Holdings, Inc. | 38 | 1 |
| Novartis AG | 39 | 1 |
| NovaTarg Therapeutics, Inc | 40 | 1 |
| Osel, Inc. | 41 | 1 |
| Sancilio &Company, Inc. | 42 | 1 |
| TaiwanJ Pharmaceuticals Co., Ltd. | 43 | 1 |
| TCM Biotech International Corp | 44 | 1 |
| Tobira Therapeutics, Inc. | 45 | 1 |
| Zafgen Inc. | 46 | 1 |
| Zydus Cadila Healthcare Limited | 47 | 1 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Assessment | 48 | 12 |
| Assessment by Monotherapy Products | 48 | 1 |
| Assessment by Combination Products | 49 | 1 |
| Assessment by Target | 50 | 3 |
| Assessment by Mechanism of Action | 53 | 3 |
| Assessment by Route of Administration | 56 | 2 |
| Assessment by Molecule Type | 58 | 2 |
| Drug Profiles | 60 | 69 |
| (leucine + metformin hydrochloride + sildenafil citrate) Drug Profile | 60 | 2 |
| (leucine + PDE5 Inhibitor) Drug Profile | 62 | 1 |
| AC-261066 Drug Profile | 63 | 1 |
| Aramchol Drug Profile | 64 | 5 |
| ARI-3037MO Drug Profile | 69 | 2 |
| AZD-4076 Drug Profile | 71 | 2 |
| C-10 Drug Profile | 73 | 2 |
| CBM-588 Drug Profile | 75 | 2 |
| cenicriviroc mesylate Drug Profile | 77 | 6 |
| CER-209 Drug Profile | 83 | 1 |
| CF-102 Drug Profile | 84 | 4 |
| CORT-118335 Drug Profile | 88 | 1 |
| dapagliflozin propanediol Drug Profile | 89 | 6 |
| DMX-300 Drug Profile | 95 | 1 |
| Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders Drug Profile | 96 | 1 |
| DUR-928 Drug Profile | 97 | 2 |
| DWP-10292 Drug Profile | 99 | 1 |
| emricasan Drug Profile | 100 | 6 |
| FLB-12 Drug Profile | 106 | 1 |
| HU-002 Drug Profile | 107 | 1 |
| KDT-501 Drug Profile | 108 | 1 |
| MAT-8800 Drug Profile | 109 | 1 |
| MN-002 Drug Profile | 110 | 1 |
| naltrexone hydrochloride Drug Profile | 111 | 2 |
| norursodeoxycholic acid Drug Profile | 113 | 1 |
| O-304 Drug Profile | 114 | 2 |
| oltipraz Drug Profile | 116 | 1 |
| pradigastat sodium Drug Profile | 117 | 2 |
| RT-200 Drug Profile | 119 | 1 |
| RT-210 Drug Profile | 120 | 1 |
| saroglitazar Drug Profile | 121 | 2 |
| SC-410 Drug Profile | 123 | 1 |
| Small Molecule for Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease Drug Profile | 124 | 1 |
| Small Molecules to Activate AMPK for Fatty Liver Disease Drug Profile | 125 | 1 |
| Small Molecules to Inhibit NaCT for Metabolic Diseases Drug Profile | 126 | 1 |
| TCM-606F Drug Profile | 127 | 1 |
| ZGN-839 Drug Profile | 128 | 1 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Dormant Projects | 129 | 2 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Discontinued Products | 131 | 1 |
| Non Alcoholic Fatty Liver Disease (NAFLD) Product Development Milestones | 132 | 11 |
| Featured News &Press Releases | 132 | 1 |
| Jun 10, 2016: NuSirt Biopharma Presents Data on NS-0200 at American Diabetes Association's 76th Annual Scientific Sessions | 132 | 1 |
| Jun 07, 2016: Galmed Pharmaceuticals Expands its Ongoing Phase IIb ARREST Study to China | 132 | 1 |
| Jun 01, 2016: Galmed Pharmaceuticals Randomizes 120th Patient in the ARREST Trial | 133 | 1 |
| May 24, 2016: Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting | 133 | 1 |
| Mar 30, 2016: Aramchol Demonstrates Significant Anti-Fibrotic Effect in a Pre-clinical Model of Fatty Liver Disease | 133 | 1 |
| Mar 01, 2016: Galmed Pharmaceuticals Announces the Enrollment of the First Patient in the ARRIVE Study | 134 | 1 |
| Jan 11, 2016: Can-Fite Announces Update on CF102 | 135 | 1 |
| Jan 06, 2016: DURECT Announces Positive Phase 1 Data for DUR-928 | 135 | 1 |
| Dec 10, 2015: NuSirt Biopharma Receives FDA Fast Track Designation for Non-Alcoholic Fatty Liver Disease Treatment | 136 | 1 |
| Dec 01, 2015: Galmed Pharmaceuticals Announces FDA Clearance of IND of Aramachol for the Treatment of Patients with HIV-Associated Lipodystrophy and Nonalcoholic Fatty Liver Disease | 137 | 1 |
| Oct 08, 2015: NuSirt Biopharma Plans Clinical Trial in Non-Alcoholic Fatty Liver Disease | 138 | 1 |
| May 18, 2015: DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study | 138 | 1 |
| Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH | 139 | 1 |
| Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting | 140 | 1 |
| Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study | 141 | 2 |
| Appendix | 143 | 2 |
| Methodology | 143 | 1 |
| Coverage | 143 | 1 |
| Secondary Research | 143 | 1 |
| Primary Research | 143 | 1 |
| Expert Panel Validation | 143 | 1 |
| Contact Us | 143 | 1 |
| Disclaimer | 144 | 1 |